Pyridinium aldoximes are best-known
therapeutic antidotes used
for clinical treatment of poisonings by organophosphorus nerve-agents
and pesticides. Recently, we found that pralidoxime (2-PAM, a currently
clinically used nerve-agent antidote) could also detoxify tetrachloro-1,4-benzoquinone
(TCBQ), which is a carcinogenic quinoid metabolite of the widely used
wood preservative pentachlorophenol under normal physiological conditions,
via an unusually mild and facile Beckmann fragmentation mechanism
accompanied by radical homolysis. However, it is not clear whether
the less-chlorinated benzoquinones (C
n
BQs, n ≤ 3) act similarly;
if so, what is the structure–activity relationship? In this
study, we found that (1) The stability of reaction intermediates produced
by different C
n
BQs and
2-PAM was dependent not only on the position but also the degree of
Cl-substitution on C
n
BQs, which can be divided into TCBQ- and DCBQ (dichloro-1,4-benzoquinone)-subgroup;
(2) The pK
a value of hydroxlated quinones
(C
n–1BQ–OHs,
the hydrolysis products of C
n
BQs), determined the stability of corresponding intermediates,
that is, the decomposition rate of the intermediates depended on the
acidity of C
n–1BQ–OHs; (3) The pK
a value of the
corresponding C
n–1BQ–OHs could also determine the reaction ratio of Beckmann
fragmentation to radical homolysis in C
n
BQs/2-PAM. These new findings on the structure–activity
relationship of the halogenated quinoid carcinogens detoxified by
pyridinium aldoxime therapeutic agents via Beckmann fragmentation
and radical homolysis reaction may have broad implications on future
biomedical and environmental research.